• 1
    Zamvil SS, Steinman LL. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8: 57962.
  • 2
    Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 122131.
  • 3
    Pender MP. Experimental autoimmune encephalomyelitis. In: PenderMP, McCombePA, eds. Autoimmune neurological disease. New York: Cambridge University Press, 1995: 2688.
  • 4
    Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001; 70: 84960.
  • 5
    Taurog JD, Argentieri DC, McReynolds RA. Adjuvant arthritis. Meth Enzymol 1988; 162: 33955.
  • 6
    Sadelain MW, Qin HY, Lauzon J et al. Prevention of type 1 diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990; 39: 5839.
  • 7
    Kies MW, Alvord EC. Prevention of allergic encephalomyelitis by prior injection of adjuvants. Nature 1958; 182: 11067.
  • 8
    Hempel K, Freitag A, Freitag B et al. Unresponsiveness to experimental allergic encephalomyelitis in Lewis rats pretreated with complete Freund's adjuvant. Int Arch Allergy Appl Immunol 1985; 76: 1939.
  • 9
    Kawano Y, Sasamoto Y, Kotake S et al. Trials of vaccination against experimental autoimmune uveoretinitis with a T-cell receptor peptide. Curr Eye Res 1991; 10: 78995.
  • 10
    Zheng CL, Hossain MA, Kukita A et al. Complete Freund's adjuvant suppresses the development and progression of pristane-induced arthritis in rats. Clin Immunol 2002; 103: 2049.
  • 11
    Gould HJ, 3rd. Complete Freund's adjuvant-induced hyperalgesia: a human perception. Pain 2000; 85: 3013.
  • 12
    Pender MP. Ascending impairment of nociception in rats with experimental allergic encephalomyelitis. J Neurol Sci 1986; 75: 31728.
  • 13
    Rabchevsky AG, Degos JD, Dreyfus PA. Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood–brain barrier without inducing reactive gliosis. Brain Res 1999; 832: 8496.
  • 14
    Namer IJ, Steibel J. Antibody directed against mannan of the Mycobacterium tuberculosis cell envelope provokes blood–brain barrier breakdown. J Neuroimmunol 2000; 103: 638.
  • 15
    Huber JD, Witt KA, Hom S et al. Inflammatory pain alters blood–brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 2001; 280: 12418.
  • 16
    Willenborg DO. Experimental allergic encephalomyelitis in Lewis rat: studies on the mechanism of recovery from disease and acquired resistance to reinduction. J Immunol 1979; 123: 114550.
  • 17
    Mostarica Stojkovic M, Vukmanovic S, Petrovic M et al. Dissection of adjuvant and suppressive effects of mycobacteria in experimental allergic encephalomyelitis production. Int Archs Allergy Appl Immun 1988; 85: 826.
  • 18
    Milicevic I, Pekovic S, Subasic S et al. Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. J Neurosci Res 2003; 72: 26878.
  • 19
    Lorentzen JC, Issazadeh S, Storch M et al. Protracted, relapsing and demyelinating autoimmune encephalomyelitis in DA rat immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 1995; 63: 193205.
  • 20
    Lenz DC, Wolf NA, Swanborg RH. Strain variation in autoimmunity. Attempted tolerization of DA rats results in the induction of experimental autoimmune encephalomyelitis. J Immunol 1999; 163: 17638.
  • 21
    Zamora A, Matejuk A, Silverman M et al. Inhibitory effects of incomplete Freund's adjuvant on experimental autoimmune encephalomyelitis. Autoimmunity 2002; 35: 218.
  • 22
    Rivers TM, Sprunt DH, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 1933; 58: 3953.
  • 23
    Levine S, Wenk EJ. Allergic encephalomyelitis. Rapid induction without the aid of adjuvants. Science 1963; 141: 52930.
  • 24
    Levine S, Wenk EJ. A hyperacute form of allergic encephalomyelitis. Am J Pathol 1965; 47: 617.
  • 25
    Alvord EC, Shaw CM, Hruby S et al. Encephalitogen-induced inhibition of experimental allergic encephalomyelitis: prevention, suppression and therapy. Ann NY Acad Sci 1965; 122: 33345.
  • 26
    Linthicum DS, Munoz JJ, Blaskett A. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell Immunol 1982; 73: 299310.
  • 27
    Munoz JJ, Bernard CC, Mackay IR. Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. Cell Immunol 1984; 83: 916.
  • 28
    Nagai Y, Akiyama K, Suzuki K et al. Minimum structural requirements for encephalitogen and for adjuvant in the induction of experimental allergic encephalomyelitis. Cell Immunol 1978; 35: 15867.
  • 29
    Root-Bernstein RS, Yurochko F, Westall FC. Clinical suppression of experimental allergic encephalomyelitis by muramyl dipeptide ‘adjuvant’. Brain Res Bull 1986; 17: 4736.
  • 30
    Robbinson D, Cockle S, Singh B et al. Native, but not genetically inactivated, pertussis toxin protects mice against experimental allergic encephalomyelitis. Cell Immunol 1996; 168: 16573.
  • 31
    Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 5008.
  • 32
    Mycko MP, Papoian R, Boschert U et al. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 2003; 126: 104857.
  • 33
    Ibrahim SM, Mix E, Bottcher T et al. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 2001; 124: 192738.
  • 34
    Steinman L, Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nature Rev Immunol 2003; 3: 48392.
  • 35
    Schnare M, Barton GM, Holt AC et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 94750.
  • 36
    Medzhitov R, Janeway CA Jr. Innate immunity: The virtues of a nonclonal system of recognition. Cell 1997; 91: 2958.
  • 37
    Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 124955.
  • 38
    Mostarica Stojkovic M, Petrovic M, Lukic ML. Resistance to the induction of EAE in AO rats: its prevention by the pretreatment with cyclophosphamide or low dose of irradiation. Clin Exp Immunol 1982; 50: 3117.
  • 39
    Lalic N, Latkovic Z, Mostarica Stojkovic M et al. Experimental allergic uveitis in the rat: Cellular characteristics and strain differences in susceptibility to the induction. Period Biol 1983; 85: 756.
  • 40
    Kleinau S, Erlandsson H, Holmdahl R et al. Adjuvant oils induce arthritis in the DA rat. Characterization of the disease and evidence for an immunological involvement. J Autoimmun 1991; 4: 87180.
  • 41
    Lukic ML, Al-Sharif R, Mostarica M et al. Immunological basis of the strain differences in susceptibility to low-dose streptozotocin-induced diabetes in rats. In: ImhofBA, Berrih-AkninS, EzineS, eds. Lymphatic tissues and in vivo immune responses. New York: Marcel Dekker, 1991: 6437.
  • 42
    Vukmanovic S, Mostarica Stojkovic M, Lukic ML. Experimental autoimmune encephalomyelitis in ‘low’ and ‘high’ interleukin 2 producer rats. I. Cellular basis of induction. Cell Immunol 1989; 121: 23742.
  • 43
    Arsov I, Pravica V, Badovinac V et al. Selection for susceptibility to experimental allergic encephalomyelitis also selects for high IFN-γ production. Transplant Proc 1995; 27: 1537.
  • 44
    Pravica V, Mostarica-Stojkovic M, Lukic ML. TNF-α and IFN-γ production correlates with the susceptibility to EAE induction in rats. Eur Cyt Network 1994; 5: 173.
  • 45
    Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 15387.
  • 46
    Swanborg RH. Experimental autoimmune encephalomyelitis in the rat. lessons in T-cell immunology and autoreactivity. Immunol Rev 2001; 184: 12935.
  • 47
    Stepaniak JA, Wolf NA, Sun D et al. Interstrain variability of autoimmune encephalomyelitis in rats: multiple encephalitogenic myelin basic protein epitopes for DA rats. J Neuroimmunol 1997; 78: 7985.
  • 48
    Miyakoshi A, Yoon WK, Jee K et al. Characterization of antigen specificity and TCR repertoire, and TCR-based DNA vaccine therapy in myelin basic protein-induced autoimmune encephalomyelitis in DA rats. J Immunol 2003; 170: 63718.
  • 49
    Dimitrijevic M, Laban O, Stanojevic S et al. Induction and reinduction of experimental allergic encephalomyelitis in DA rats: the effect of age and encephalitogen. Acta Vet 2000; 50: 28996.
  • 50
    Gordon FL, Nguyen KB, White CA et al. Rapid entry and downregulation of T cells in the central nervous system during the reinduction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2001; 112: 1527.
  • 51
    Sun D, Qin Y, Chluba J et al. Suppression of experimentally induced autoimmune encephalomyelitis by cytolotic T–T interactions. Nature 1988; 332: 8435.
  • 52
    Kahn DA, Archer DC, Gold DP et al. Adjuvant immunotherapy is dependent on inducible nitric oxide synthase. J Exp Med 2001; 193: 12618.
  • 53
    Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54: 113.